The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients

Graham F Pineo1
Jay Lin 2
Lieve Annemans 3
1Department of Medicine, University of Calgary, Calgary, Alberta, Canada; 2Novosys Health, Flemington, NJ, USA; 3Department of Medicine, Ghent University, Ghent and Brussels University, Brussels, Belgium

Abstract: Venous thromboembolism (VTE) is a common complication after acute ischemic stroke that can be prevented by the use of anticoagulants. Current guidelines from the American College of Chest Physicians recommend that patients with acute ischemic stroke and restricted mobility receive prophylactic low-dose unfractionated heparin or a low-molecular-weight heparin. Results from clinical studies, most recently from PREVAIL (PREvention of Venous Thromboembolism After Acute Ischemic Stroke with LMWH and unfractionated heparin), suggest that the low-molecular-weight heparin, enoxaparin, is preferable to unfractionated heparin for VTE prophylaxis in patients with acute ischemic stroke and restricted mobility. This is due to a better clinical benefit-to-risk ratio, with the added convenience of once-daily administration. In line with findings from modeling studies and real-world data in acutely ill medical patients, recent economic data indicate that the higher drug cost of enoxaparin is offset by the reduction in clinical events as compared with the use of unfractionated heparin for the prevention of VTE after acute ischemic stroke, particularly in patients with severe stroke. With national performance measures highlighting the need for hospitals to examine their VTE practices, the relative costs of different regimens are of particular importance to health care decision-makers. The data reviewed here suggest that preferential use of enoxaparin over unfractionated heparin for the prevention of VTE after acute ischemic stroke may lead to reduced VTE rates and concomitant cost savings in clinical practice.

Keywords: acute ischemic stroke, cost savings, enoxaparin, unfractionated heparin, venous thromboembolism

Introduction
Worldwide, stroke is the second leading cause of death1 and its impact is expected to increase with the westernization of lifestyles in developing countries. In addition to high rates of mortality, stroke is responsible for significant long-term morbidity, with permanent disability experienced by 15%–30% of stroke patients and 20% of patients requiring institutional care at 3 months after onset.2 There is also a considerable health care burden associated with long-term morbidity due to stroke, such that the total (direct and indirect) costs of stroke were estimated to be $73.9 billion in 2010 in the United States alone.3

Approximately 85% of all strokes are ischemic events2,3 that usually occur as a result of thrombosis or embolism. Venous thromboembolism (VTE) is also a common, yet highly preventable, complication following stroke.4 To reduce the...
The incidence of VTE in patients with acute ischemic stroke and restricted mobility, guidelines from the American College of Chest Physicians recommend prophylaxis with low-dose unfractionated heparin or a low-molecular-weight heparin (LMWH). Although none of the LMWHs is indicated for thromboprophylaxis specifically in patients with acute ischemic stroke, these patients are often categorized as medical patients with reduced mobility, a group of patients for which the LMWHs dalteparin and enoxaparin are indicated for thromboprophylaxis.

This review discusses the risk of VTE in stroke patients, describes studies evaluating the efficacy and safety of VTE prophylaxis after acute ischemic stroke, and details the relative costs of different thromboprophylaxis regimens, with particular emphasis on data from the PREVAIL (PREvention of Venous Thromboembolism After Acute Ischemic Stroke with LMWH and UFH) study.6–8

Thromboembolic risk in stroke patients

Following a first stroke, patients are at significantly increased risk of a further thrombotic event, ie, VTE (deep vein thrombosis or pulmonary embolism), recurrent stroke, or myocardial infarction. A recent study of 1,150,336 adult hospitalizations with ischemic stroke in the United States using data from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project, demonstrated that although inhospital mortality decreased from 1998–1999 to 2006–2007, the largest increase in medical complications in these patients was observed for deep vein thrombosis (0.46% versus 0.79%) and pulmonary embolism (0.11% versus 0.27%). In the absence of thromboprophylaxis, 20%–75% of stroke patients may develop deep vein thrombosis, with the wide range depending on the methods used to detect deep vein thrombosis and the degree of lower limb paralysis.10,11 Pulmonary embolism is fatal in up to half of all cases.12 Indeed, pulmonary embolism is the third most common cause of death in stroke patients, after stroke itself and secondary infections, occurring in 1%–2% of patients.12 The risk of VTE is highest in the 14 days after stroke; however, deep vein thrombosis was present in 14%–33% of stroke patients in rehabilitation over 2 weeks after the primary event.12

Stroke patients are at increased risk of VTE as a result of their initial stroke and its consequences, such as limb paralysis. In line with other acutely ill medical patients, stroke patients often have multiple other complications, such as advanced age, immobility, obesity, and venous insufficiency. Comorbidities that further increase VTE risk are also common, including cancer, heart failure, and severe respiratory disease.13 For example, in the total patient population of a trial of thromboprophylaxis for the prevention of deep vein thrombosis in acute ischemic stroke, 52% of patients were aged over 70 years, 18% were obese, and 9% had varicose veins.14

Preventing VTE after acute ischemic stroke: the role of antithrombotic agents

Given the high risk and considerable consequences, prevention of VTE is crucially important following a stroke. However, it is essential to rule out hemorrhagic stroke and identify patients at increased risk of bleeding complications before prescribing pharmacological prophylaxis. Current guidelines from the American College of Chest Physicians recommend that patients with acute ischemic stroke and restricted mobility receive prophylactic low-dose subcutaneous unfractionated heparin or LMWH (Grade 1A). For patients who have contraindications to anticoagulants, intermittent pneumatic compression devices or elastic stockings are recommended (Grade 1B). Guidelines from the American Heart Association/American Stroke Association also recommend subcutaneous administration of anticoagulants in immobilized patients with acute ischemic stroke to prevent deep vein thrombosis (Class I, level of evidence A).15 These guidelines consider aspirin a potential intervention to prevent deep vein thrombosis, but note that it is less effective than anticoagulants (Class IIA, level of evidence A).15 Recent guidelines from the American College of Physicians recommend pharmacologic prophylaxis with unfractionated heparin or a LMWH, or a related drug for VTE in medical patients (including stroke patients) unless the assessed risk for bleeding outweighs the likely benefits.16

Unfractionated heparin

Thromboprophylaxis with unfractionated heparin has been shown to reduce the incidence of VTE after acute ischemic stroke compared with placebo.10,17,18 Sandecock et al reviewed four small trials in stroke patients and reported an overall reduction of 84% in VTE events with unfractionated heparin prophylaxis versus placebo or no treatment. However, data were inadequate to enable conclusions to be drawn on the safety of unfractionated heparin prophylaxis, particularly with respect to hemorrhagic transformation and bleeding in patients with known intracerebral hemorrhage.17 Systematic screening for hemorrhagic transformation in patients with cerebral infarcts would be able to provide firm
evidence of this complication, but none of the trials analyzed has this as a prespecified analysis. Also, the included studies were too small to provide firm conclusions regarding safety.17 Subsequently, the International Stroke Trial, a large randomized study (approximately 20,000 patients), investigated the efficacy and safety of unfractionated heparin administered at either 5000 IU or 12,500 IU twice daily.18 Taken together, unfractionated heparin significantly reduced the incidence of pulmonary embolism compared with control (0.5% versus 0.8%; \( P < 0.05 \)), but was associated with a significant increase in hemorrhagic stroke (1.2% versus 0.4%; \( P < 0.001 \)) and bleeding complications (1.3% versus 0.4%; \( P < 0.001 \)).18

**Low-molecular-weight heparins**

Outcomes following prophylaxis with LMWHs or danaparoid, a heparinoid, were investigated in a meta-analysis of 10 small controlled trials \((n = 2855)\).19 LMWHs/danaparoid versus control was associated with significant reductions in prospectively identified deep vein thrombosis (odds ratio [OR] 0.27; 95% confidence interval [CI] 0.08–0.96) and symptomatic pulmonary embolism (OR 0.34; 95% CI 0.17–0.69). However, significant increases in major extracranial hemorrhage were observed with LMWHs (OR 2.17; 95% CI 1.10–4.28).

Subsequently, a number of head-to-head studies have compared LMWHs with unfractionated heparin for the prevention of VTE after stroke.6,14,19,20 In one study, unfractionated heparin 5000 IU three times daily and the LMWH enoxaparin administered at 40 mg once daily were investigated in 212 patients.14 The main outcome measures of symptomatic or asymptomatic deep vein thrombosis detected by venography, pulmonary embolism, death from any cause, intracranial hemorrhage including hemorrhagic infarction, or any other major bleeding occurred in 37.7% of patients in the enoxaparin group and 49.1% in the unfractionated heparin group \((P = 0.127)\). Bleeding complications were experienced by 2.8% of patients in the enoxaparin group and 1.9% in the unfractionated heparin group. Of note, numerically fewer patients treated with enoxaparin (13.2%) compared with unfractionated heparin (18.9%) had evidence of hemorrhagic transformation of acute ischemic stroke.

The PROTECT study (Prophylaxis of Thromboembolic Events by Certoparin Trial) compared the LMWH certoparin (3000 U anti-Xa once daily; \(n = 272\)) with unfractionated heparin (5000 IU three times daily; \(n = 273\)) in the prevention of VTE following stroke.21 The composite primary endpoint of proximal symptomatic or asymptomatic deep vein thrombosis detected by ultrasonography, pulmonary embolism, or death related to VTE during treatment occurred in 7.0% of patients in the certoparin group compared with 9.7% in the unfractionated heparin group, demonstrating that certoparin was as effective as unfractionated heparin \((P = 0.0011\) for noninferiority). Major bleeding occurred in 1.1% of patients allocated to certoparin and 1.8% of patients allocated to unfractionated heparin.

In the PREVAIL (PREvention of Venous Thromboembolism After Acute Ischemic Stroke with LMWH and unfractionated heparin) study of 1762 patients with acute ischemic stroke and restricted mobility, enoxaparin at a dose of 40 mg once daily reduced the risk of the composite primary endpoint of symptomatic or asymptomatic deep vein thrombosis, detected by contrast venography, or symptomatic or fatal pulmonary embolism by 43% compared with unfractionated heparin 5000 IU twice daily (10% versus 18%, respectively; relative risk 0.57; 95% CI 0.44–0.76; \(P = 0.0001\)).6 Bleeding complications were similar between groups (both 8%). The composite of symptomatic intracranial and major extracranial hemorrhage was not significantly different between enoxaparin and unfractionated heparin \((11/877 [1.2%] \text{ versus } 6/872 [0.7%]; \ P = 0.23)\), but there was a slight, clinically significant, excess in major extracranial hemorrhage alone with enoxaparin compared with unfractionated heparin \((7/877 [0.8%] \text{ versus } 0/872 [0.0%]; \ P = 0.015)\).

In the PREVAIL study, the rate of VTE was higher in patients with more severe strokes (National Institutes of Health Stroke Scale [NIHSS] scores \(\geq 14\)) than less severe strokes (NIHSS scores \(< 14\)). Prophylaxis with enoxaparin was associated with a reduced risk of VTE compared with unfractionated heparin in both stroke severity groups (Figure 1).6 Further, a post hoc analysis of data from the PREVAIL study indicate that enoxaparin prophylaxis confers a reduced risk of VTE, as compared with unfractionated heparin, in multiple patient subgroups. This includes several subgroups with or without risk factors in addition to stroke, such as patients with diabetes, obesity, and advanced age (Figure 1).6,22 More recently, a subanalysis of PREVAIL has been conducted to study the long-term neurological outcomes associated with the use of enoxaparin compared with unfractionated heparin.23 Similar improvements in NIHSS and modified Rankin scale scores were observed in both groups over the 90-day follow-up period. The incidence of intracranial hemorrhage was similar in the enoxaparin group and the unfractionated heparin group (2.3% versus 2.5%, respectively).

Data from PREVAIL, PROTECT, and seven other randomized studies were analyzed in a Cochrane review
of LMWHs/heparinoid versus unfractionated heparin in 3137 patients with acute ischemic stroke. Allocation to the LMWH group was associated with a reduction in deep vein thrombosis compared with unfractionated heparin (OR 0.55; 95% CI 0.44–0.70); however, the authors concluded that there were too few data to provide reliable information regarding their effects on other important outcomes, including death and intracranial hemorrhage.

Other anticoagulant agents

Several other anticoagulant agents have been studied in medical patients or are currently being assessed in randomized controlled trials. These include fondaparinux, rivaroxaban, and apixaban. Fondaparinux (2.5 mg once daily, for 6–14 days) reduced VTE in older acute medical patients compared with placebo, with a relative risk reduction of 46.7% (95% CI 7.7–69.3). No concomitant increase in major bleeding events, which occurred in 0.2% of patients in both groups, was associated with fondaparinux. MAGELLAN (Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin) has recently been completed, and ADOPT (A Phase III Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization) is currently underway. These trials are designed to assess the use of extended duration prophylaxis with apixaban and rivaroxaban, for 30 and 35 days, respectively, in comparison with enoxaparin during hospitalization (6–14 days) and placebo after hospital discharge. Preliminary results from MAGELLAN showed that rivaroxaban 10 mg once daily was noninferior to enoxaparin 40 mg once daily for the primary endpoint of major VTE (asymptomatic and symptomatic proximal deep vein thrombosis, nonfatal pulmonary embolism, and VTE-related death) at day 10 ± 4 (2.7% versus 2.7%; P for noninferiority = 0.0025). For the extended period of rivaroxaban (35 ± 4 days) versus placebo, rivaroxaban was superior (4.4% versus 5.7%; P = 0.02). Clinically relevant bleeding rates

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Favors enoxaparin OR (95% CI)</th>
<th>Favors UFH OR (95% CI)</th>
<th>P for interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke-prophylaxis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24–48 h</td>
<td>0.59 (0.40–0.87)</td>
<td>0.39 (0.22–0.68)</td>
<td>0.23</td>
</tr>
<tr>
<td>Stroke-prophylaxis &lt;24 h</td>
<td>0.53 (0.28–1.00)</td>
<td>0.51 (0.35–0.74)</td>
<td>0.93</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0.57 (0.31–1.07)</td>
<td>0.50 (0.34–0.72)</td>
<td>0.71</td>
</tr>
<tr>
<td>No diabetes</td>
<td>0.47 (0.27–0.83)</td>
<td>0.47 (0.27–0.78)</td>
<td>0.98</td>
</tr>
<tr>
<td>Obesity</td>
<td>0.54 (0.36–0.79)</td>
<td>0.54 (0.36–0.79)</td>
<td>0.37</td>
</tr>
<tr>
<td>No obesity</td>
<td>0.56 (0.37–0.84)</td>
<td>0.56 (0.37–0.84)</td>
<td>0.80</td>
</tr>
<tr>
<td>NIHSS score ≥14</td>
<td>0.46 (0.27–0.78)</td>
<td>0.55 (0.35–0.85)</td>
<td>0.71</td>
</tr>
<tr>
<td>NIHSS score &lt;14</td>
<td>0.50 (0.32–0.79)</td>
<td>0.50 (0.32–0.79)</td>
<td>0.29</td>
</tr>
<tr>
<td>Female</td>
<td>0.72 (0.41–1.28)</td>
<td>0.72 (0.41–1.28)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>0.38 (0.22–0.67)</td>
<td>0.52 (0.31–0.89)</td>
<td></td>
</tr>
<tr>
<td>Age &gt;75 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 65–75 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;65 years</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 1** Relative risk of venous thromboembolism for enoxaparin compared with UFH in patients with acute ischemic stroke by patient characteristics in the PREVAIL (PREvention of Venous Thromboembolism After Acute Ischemic Stroke with LMWH [low-molecular-weight heparin] and UFH) study. Reproduced from Sherman DG, et al. Lancet. 2007;369:1347–55 © 2007, with permission from Elsevier.

Abbreviations: CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; UFH, unfractionated heparin.
were low but significantly higher with rivaroxaban across the entire study (2.8% versus 1.2%; \( P < 0.0001 \) for days 1–10 and 1.4% versus 0.5%; \( P < 0.0001 \) for days 11–35). Subgroup analysis confirmed the overall efficacy and bleeding results for most clinical groups including patients with acute ischemic stroke, although the number of patients with acute ischemic stroke was small.\(^{23} \) Furthermore, rivaroxaban, apixaban, and the thrombin inhibitor, dabigatran, have been assessed for the prevention of stroke and systemic embolism in patients with atrial fibrillation.\(^{26–28} \) However, no studies are currently underway directly assessing the efficacy of these agents in reducing VTE following acute ischemic stroke.

**Mechanical prophylaxis**

Intermittent pneumatic compression devices or graduated compression stockings are recommended as thromboprophylaxis for patients who have contraindications to anticoagulants. The relationship between symptomatic VTE and the use of stockings was assessed based on observational data from TAIST (the Tinzaparin in Acute Ischemic Stroke Trial) which compared the LMWH, tinzaparin, (175 IU/kg or 100 IU/kg) with aspirin 300 mg.\(^{29} \) Patients wearing bilateral graduated compression stockings for 10 days (\( n = 374 \) had a nonsignificant one-third reduction in the odds of VTE as compared with those who wore no stockings or wore them for less than 10 days (OR 0.65; 95% CI 0.26–1.65).

The large CLOTS (Clots in Legs Or sTockings after Stroke) trials were designed to investigate further the role of mechanical prophylaxis for preventing VTE in patients with acute stroke. In CLOTS trial 1 of 2518 immobile patients with acute ischemic stroke, symptomatic or asymptomatic proximal deep vein thrombosis, detected by ultrasonography, occurred in 10.0% of patients allocated to thigh-length graduated compression stockings and in 10.5% allocated to avoid graduated compression stockings, resulting in a nonsignificant one-third reduction in the odds of VTE as compared with those who wore no stockings or wore them for less than 10 days (OR 0.65; 95% CI 0.26–1.65).\(^{30} \) Skin breaks, ulcers, blisters, and skin necrosis were more common in patients allocated graduated compression stockings than in the control group (5% versus 1%, respectively; OR 4.18; 95% CI 2.40–7.27). In CLOTS trial 2 (\( n = 3114 \), symptomatic or asymptomatic proximal deep vein thrombosis, detected by ultrasonography, occurred in 6.3% of patients who received thigh-length stockings and 8.8% who received below-knee stockings, an odds reduction of 31% (95% CI 9–47; \( P = 0.008 \) for the absolute difference).\(^{31} \) Skin breaks occurred in 3.9% of patients who received thigh-length stockings and 2.9% of patients who received below-knee stockings (OR 1.38; 95% CI 0.93–2.04; \( P = 0.11 \)). These results are intriguing because it seems that thigh-length stockings were ineffective in trial 1, but more effective than below-knee stockings in trial 2. Further information on the use of mechanical prophylaxis will be obtained from the ongoing CLOTS trial 3, which is investigating the use of intermittent pneumatic compression versus avoidance of intermittent pneumatic compression.

**Cost comparisons**

Recently, there has been an increased focus on the total cost of different medical regimens within hospitals in the United States. Such studies take drug-acquisition costs into consideration and also costs for clinical events (Table 1).\(^{7,8,32–34} \) Two studies using a cost-effectiveness analysis model based on hypothetical cohorts of medically ill patients have investigated the cost-effectiveness of enoxaparin and unfractionated heparin.\(^{32,33} \) In a simulated cohort of 10,000 patients using a decision-analytic model with parameter estimates derived from published clinical trials, expected numbers of deaths attributable to VTE or drug complications were 37 with enoxaparin 40 mg once daily, 53 with unfractionated heparin 5000 IU twice daily, and 81 with no prophylaxis.\(^{32} \) In 2001, corresponding expected costs of prevention, diagnosis, and management of VTE were \$3,502,000 for enoxaparin, \$3,772,000 for unfractionated heparin, and \$3,105,000 for no prophylaxis. The incremental cost per death averted with enoxaparin prophylaxis versus no prophylaxis was \$9100. Enoxaparin was a dominant strategy over unfractionated heparin by being both more effective and less costly.

In a more recent study by Deitelzweig et al.,\(^{31} \) a decision-analytic model, with model parameters derived from published clinical trials and other secondary sources, compared the long-term clinical effectiveness, safety, and direct medical costs between hypothetical cohorts of 10,000 medical patients receiving enoxaparin 40 mg once daily, unfractionated heparin 5000 IU twice daily, or no prophylaxis. The estimated incidence of VTE at 2 years (including recurrent VTE) was 6.8% with enoxaparin, 7.9% with unfractionated heparin, and 17.9% with no prophylaxis. Two-year mortality occurred in 15.7% of enoxaparin patients and 16.0% of unfractionated heparin patients. The incidence of major bleeding was 0.7%, 1.2%, and 0.6% for enoxaparin, unfractionated heparin, and no prophylaxis, respectively. Total average costs per patient were \$1264 for enoxaparin, \$1585 for unfractionated heparin, and \$2245 for no prophylaxis; therefore, enoxaparin was dominant over the two alternative strategies. No realistic parameter changes resulted in prophylaxis using enoxaparin being more costly than unfractionated heparin prophylaxis.
In a 2006 study, costs were investigated in different medical patient groups at risk of VTE who received a LMWH or unfractionated heparin based on real-world data from a large inpatient database. In the 153,552 patients with acute ischemic stroke, the mean ± standard deviation total drug cost per patient was $803 ± 993 in the LMWH group and $617 ± 2701 in the unfractionated heparin group. Importantly, the mean total hospital cost per patient was $8608 ± 7190 for enoxaparin and $8911 ± 8291 for unfractionated heparin.

Recently, data from PREVAIL were used to investigate the economic impact further, from the payer perspective and the hospital perspective, of a LMWH versus unfractionated heparin specifically in patients after acute ischemic stroke.7,8 For the payer perspective, payer costs for clinical events were based on the median cost in Centers for Medicare and Medicaid Services claim information. The average costs of clinical events per patient to the payer were $1758 with enoxaparin and $2854 for unfractionated heparin, resulting in a net saving of $1096 with enoxaparin. The drug costs were higher for enoxaparin than unfractionated heparin ($260 versus $59, respectively); however, when the total cost of clinical events and drug costs were considered together, enoxaparin was associated with a total cost saving of $895 per patient compared with unfractionated heparin ($2018 with enoxaparin versus $2913 with unfractionated heparin).

In addition to this model scenario that used the VTE definition from the PREVAIL study, which includes symptomatic or asymptomatic deep vein thrombosis, symptomatic pulmonary embolism, or fatal pulmonary embolism, two other model scenarios were used to calculate costs in order to account for different definitions of VTE. The second model scenario grouped events into two categories, major VTE including pulmonary embolism, symptomatic deep vein thrombosis and asymptomatic proximal deep vein thrombosis, and minor VTE defined as asymptomatic distal deep vein thrombosis only. The third model scenario used the European Committee for Medicinal Products for Human Use (CHMP) definition, which includes well documented proximal deep vein thrombosis, well documented nonfatal pulmonary embolism, and death from all causes including pulmonary embolism. Only the definition of efficacy endpoints changed between the three scenarios and the definition of bleeding was consistent across all models, and included intracranial hemorrhage, major extracranial hemorrhage, and minor hemorrhage for all three model scenarios. Despite higher drug costs for enoxaparin compared with unfractionated heparin, total cost per patient remained lower for enoxaparin in all three scenarios.

### Table 1 Cost comparison studies for use of unfractionated heparin versus enoxaparin for thromboprophylaxis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patient population</th>
<th>Parameter estimates</th>
<th>Cost estimate</th>
<th>Drug acquisition cost, $</th>
<th>Total cost, $</th>
</tr>
</thead>
<tbody>
<tr>
<td>McGarry et al32</td>
<td>Medical patients</td>
<td>Decision-analytic model based on a hypothetical cohort (n = 10,000); model parameters based on clinical trials and other secondary sources</td>
<td>Cost per patient (30 days)</td>
<td>112</td>
<td>172</td>
</tr>
<tr>
<td>Deitelzweig et al33</td>
<td>Medical patients</td>
<td>Decision-analytic model based on a hypothetical cohort (n = 10,000); model parameters based on clinical trials and other secondary sources</td>
<td>Cost per patient (2 years)</td>
<td>68</td>
<td>211</td>
</tr>
<tr>
<td>Burleigh et al34</td>
<td>Acute ischemic stroke subpopulation</td>
<td>Real-world data from a large inpatient database (n = 153,552 ischemic stroke patients)</td>
<td>Hospital cost per patient</td>
<td>617</td>
<td>803</td>
</tr>
<tr>
<td>Pineo et al7</td>
<td>Acute ischemic stroke</td>
<td>Decision-analytic model based on PREVAIL clinical trial</td>
<td>Payer cost per patient</td>
<td>59</td>
<td>260</td>
</tr>
<tr>
<td>Pineo et al8</td>
<td>Acute ischemic stroke</td>
<td>Decision-analytic model based on PREVAIL clinical trial</td>
<td>Hospital cost per patient</td>
<td>259</td>
<td>360</td>
</tr>
</tbody>
</table>

**Abbreviations:** PREVAIL, PREvention of Venous Thromboembolism After Acute Ischemic Stroke with LMWH [low-molecular-weight heparin] and UFH; UFH, unfractionated heparin.
over unfractionated heparin resulted in even greater total cost-savings ($1800 per patient) than in patients with less severe stroke (NIHSS scores < 14; $488 per patient).

In a similar analysis, costs for hospitals were evaluated rather than costs to the payer. The costs of clinical events for hospitals were based on mean hospital costs in the Premier Perspective™ multihospital database, which is one of the largest United States hospital clinical and economic databases. This database contains detailed United States inpatient care records from over 600 hospitals of principal and secondary diagnoses, inpatient procedures, administered laboratory tests, dispensed drugs, and demographic information. The average cost to the hospital, when taking into account the costs of VTE and bleeding, was similarly lower with enoxaparin than with unfractionated heparin ($422 versus $662, respectively), with a net saving of $240 per patient if enoxaparin was used. The drug costs, including drug administration costs, were higher for enoxaparin than unfractionated heparin ($360 versus $259, respectively); however, when the total cost of clinical events and drug costs were considered together, enoxaparin was associated with a total cost saving of $140 per patient compared with unfractionated heparin ($782 with enoxaparin versus $922 with unfractionated heparin). Again, the total hospital cost savings were greater when enoxaparin was used instead of unfractionated heparin in patients with more severe stroke (cost-saving $287 if NIHSS score ≥ 14 versus $71 if NIHSS score < 14). Sensitivity analyses were performed where cost parameters were varied by ±5%, ±10%, ±15%, ±30%, and ±40%; enoxaparin remained less costly than unfractionated heparin in all cases. In a multivariate analysis, differences in enoxaparin drug costs, hospital costs for deep vein thrombosis, and probability of deep vein thrombosis for patients on enoxaparin were the factors with the greatest effect on the overall cost. The only scenario where the higher drug cost of prophylaxis with enoxaparin was not completely offset by the reduction in events compared with unfractionated heparin, was a scenario which used a published ratio of asymptomatic deep vein thrombosis to symptomatic VTE to account for the fact that not all VTE events in the real-world present with symptoms prompting treatment and, therefore, costs. This scenario was limited by the fact that the ratio was derived from different patient populations receiving different anticoagulants than stroke patients.

The Joint Commission and the National Quality Forum in the United States have recently introduced a set of quality assurance measures within the “National Consensus Standards for the Prevention and Care of Venous Thromboembolism” project, with the specific goal of improving inhospital VTE assessment, diagnosis, prophylaxis, and treatment. Three process measures focus on VTE prevention, ie, VTE-1 assesses the proportion of patients who received any prophylaxis, VTE-2 evaluates prophylaxis after admission to the intensive care unit, and VTE-6 assesses the incidence of potentially preventable hospital-acquired VTE. With national performance measures highlighting the need for hospitals to examine their VTE practices, the relative costs of different regimens are of particular importance to health care decision-makers. The use of clinically effective and cost-effective prophylaxis regimens should help to prevent VTE and its clinical and economic consequences, and ensure hospitals meet performance measures. In addition, the CMS has recognized hospital-acquired VTE as a preventable condition. CMS have classified VTE after total knee or hip replacement as a preventable hospital-acquired condition and will not pay any incremental costs, leaving hospitals to bear the financial burden. Whether this or other financial-based incentives will be extended to include VTE after acute ischemic stroke remains to be seen.

Conclusion

VTE is a common complication after acute ischemic stroke. Although none of the LMWHs is indicated for thromboprophylaxis specifically in patients with acute ischemic stroke, guidelines from the American College of Chest Physicians recommend that patients with acute ischemic stroke and restricted mobility receive prophylactic low-dose subcutaneous unfractionated heparin or a LMWH, unless contraindicated. Results from clinical studies suggest that enoxaparin is preferable to unfractionated heparin for VTE prophylaxis in patients with acute ischemic stroke and restricted mobility due to a better clinical benefit-to-risk ratio, with the added convenience of once-daily administration. In line with findings from modeling studies and real-world data in acutely ill medical patients, recent economic data indicate that the higher drug cost of enoxaparin is offset by the reduction in clinical events as compared with the use of unfractionated heparin for the prevention of VTE, particularly in patients with severe stroke. However, this cost-analysis in stroke patients is based on one open-label, randomized, controlled trial only. The data reviewed here suggest that preferential use of enoxaparin over unfractionated heparin may lead to reduced VTE rates and concomitant cost-savings in clinical practice. Furthermore, a once-daily injection has the advantage in clinical practice of simplifying treatment and improving compliance with both patients and physicians,
decreasing nursing time, and providing prophylaxis in an outpatient setting in addition to decreasing costs.77

Disclosure
The authors received editorial and writing support in the preparation of this manuscript from Hester van Lier, PhD, of Excerpta Medica, funded by sanofi-aventis US Inc. Graham Pineo was a member of the Steering Committee for the PREVAIL study and has received honoraria and consulting fees from sanofi-aventis, Boehringer-Ingelheim, Bayer, and BMS/Pfizer.

References
10. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the outpatient setting in addition to decreasing costs.77


